Back HBV Prevention HBV Vaccines

HBV Vaccines

HIV Controllers Respond Better to Hepatitis B Vaccine

HIV positive natural controllers who maintain undetectable or low viral load without antiretroviral therapy (ART) are more likely to achieve adequate response to hepatitis B virus (HBV) vaccination and have improved survival, according to a study published in the August 21 edition of the open-access journal PLoS ONE.

alt

Read more:

EASL 2014: Sci-B-Vac Bests Engerix-B for Preventing Mother-to-Child HBV Transmission

An investigational vaccine known as Sci-B-Vac given to babies born to women with hepatitis B was more effective at preventing HBV infection than the widely used Engerix-B vaccine, according to a report at the EASL International Liver Congress this month in London.

alt

Read more:

AASLD 2013: Hepatitis B Vaccine Protection Lasts at Least 30 Years

Hepatitis B vaccination provides long-term protection through 30 years for a majority of recipients, and more than 90% were protected with either initial immunization or a booster, according to a presentation at the 64th AASLD Liver Meeting last week in Washington, DC.

alt

Read more:

CDC Updates Guidance for Hepatitis B Vaccination of Health-care Providers

The U.S. Centers for Disease Control and Prevention (CDC) has published updated guidance for evaluating and ensuring protection against hepatitis B virus (HBV) for health-care workers, as well as post-exposure prophylaxis recommendations for those without adequate vaccine protection.

alt

Read more:

FDA Rejects Heplisav Hepatitis B Vaccine Seeking More Safety Data

The U.S. Food and Drug Administration (FDA) has declined to approve Dynavax Technologies' experimental hepatitis B virus (HBV) vaccine candidate with a toll-like receptor 9 adjuvant, stating it wants to see further data on safety in adults including seniors, the company announced this week.

alt

Read more: